tradingkey.logo

Regenxbio Reports New Positive Interim Data From Phase I/II Affinity Duchenne® Trial Of Rgx-202

ReutersMar 11, 2026 4:48 PM

- Regenxbio Inc RGNX.O:

  • REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

  • REGENXBIO INC - NO SERIOUS ADVERSE EVENTS OBSERVED IN PHASE I/II STUDY

  • REGENXBIO INC - PIVOTAL TOPLINE DATA EXPECTED IN Q2 2026

  • REGENXBIO INC - TO REQUEST PRE-BLA MEETING WITH FDA IN MID-2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

KeyAI